Thecoma

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 1353 Experts worldwide ranked by ideXlab platform

Howard W. Jones - One of the best experts on this subject based on the ideXlab platform.

Massimo Di Maio - One of the best experts on this subject based on the ideXlab platform.

  • luteinized Thecoma Thecomatosis with sclerosing peritonitis a systematic review of the literature of the last 25 years
    Expert Review of Anticancer Therapy, 2020
    Co-Authors: Leonardo Muratori, Elena Trevisi, Marco Donatello Delcuratolo, Paola Sperone, Massimo Di Maio
    Abstract:

    Luteinized Thecoma (Thecomatosis) with sclerosing peritonitis (LTSP) is a very uncommon syndrome, characterized by the presence of single or bilateral ovarian Thecomas and peritoneal fibrotic lesio...

  • Luteinized Thecoma (Thecomatosis) with sclerosing peritonitis: a systematic review of the literature of the last 25 years.
    Expert review of anticancer therapy, 2020
    Co-Authors: Leonardo Muratori, Elena Trevisi, Marco Donatello Delcuratolo, Paola Sperone, Massimo Di Maio
    Abstract:

    INTRODUCTION Luteinized Thecoma (Thecomatosis) with sclerosing peritonitis (LTSP) is a very uncommon syndrome, characterized by the presence of single or bilateral ovarian Thecomas and peritoneal fibrotic lesions. The disease occurs in young women and it can lead to peritoneal fibrosis and bowel obstruction. The pathogenesis of this syndrome remains still largely unknown. Surgery represents the cornerstone of treatment, but resection alone does not always allow a complete disease control. Attempts at medical treatments have been reported in recent years, but a real standard therapy has not yet been defined. AREAS COVERED We performed a systematic review of literature, collecting all the papers that reported cases of LTSP, since its first description in 1994. We found that, in these 25 years, less than 50 cases have been described in literature. EXPERT OPINION Along with the established role of surgery, adjuvant treatment with hormonal agents, in particular in estrogen receptor expression, seems to be a promising approach. However, more efforts must be carried out to describe treatment and outcome of new cases, improving knowledge about this rare condition.

Laura Williams - One of the best experts on this subject based on the ideXlab platform.

Leonardo Muratori - One of the best experts on this subject based on the ideXlab platform.

  • luteinized Thecoma Thecomatosis with sclerosing peritonitis a systematic review of the literature of the last 25 years
    Expert Review of Anticancer Therapy, 2020
    Co-Authors: Leonardo Muratori, Elena Trevisi, Marco Donatello Delcuratolo, Paola Sperone, Massimo Di Maio
    Abstract:

    Luteinized Thecoma (Thecomatosis) with sclerosing peritonitis (LTSP) is a very uncommon syndrome, characterized by the presence of single or bilateral ovarian Thecomas and peritoneal fibrotic lesio...

  • Luteinized Thecoma (Thecomatosis) with sclerosing peritonitis: a systematic review of the literature of the last 25 years.
    Expert review of anticancer therapy, 2020
    Co-Authors: Leonardo Muratori, Elena Trevisi, Marco Donatello Delcuratolo, Paola Sperone, Massimo Di Maio
    Abstract:

    INTRODUCTION Luteinized Thecoma (Thecomatosis) with sclerosing peritonitis (LTSP) is a very uncommon syndrome, characterized by the presence of single or bilateral ovarian Thecomas and peritoneal fibrotic lesions. The disease occurs in young women and it can lead to peritoneal fibrosis and bowel obstruction. The pathogenesis of this syndrome remains still largely unknown. Surgery represents the cornerstone of treatment, but resection alone does not always allow a complete disease control. Attempts at medical treatments have been reported in recent years, but a real standard therapy has not yet been defined. AREAS COVERED We performed a systematic review of literature, collecting all the papers that reported cases of LTSP, since its first description in 1994. We found that, in these 25 years, less than 50 cases have been described in literature. EXPERT OPINION Along with the established role of surgery, adjuvant treatment with hormonal agents, in particular in estrogen receptor expression, seems to be a promising approach. However, more efforts must be carried out to describe treatment and outcome of new cases, improving knowledge about this rare condition.

Guo-ping Fang - One of the best experts on this subject based on the ideXlab platform.